Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Assess the Efficiency of Trastuzumab Deruxtecan in Russian Breast Cancer Patients
Sponsor: Blokhin's Russian Cancer Research Center
Summary
This multi-center observational retrospective study will collect real-world clinical data from eligible patients with unresectable or metastatic HER2+ breast cancer who have received one or more cycles Trastuzumab Deruxtecan in Russian Federation
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2025-12
Completion Date
2026-05
Last Updated
2025-12-15
Healthy Volunteers
No
Interventions
T-DXd 5.4 mg/kg, IVD, 1 cycle every 21 days.
T-DXd 5.4 mg/kg, IVD, 1 cycle every 21 days. Intravenous infusion
Locations (1)
Federal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" оf the Ministry of Health of the Russian Federation
Moscow, Russia